Company
Headquarters: Copenhagen, Denmark
Employees: 3
kr514.0 Million
SEK as of July 1, 2024
US$48.4 Million
Company | Market Cap (USD) |
---|---|
Intuitive | $193.76 B |
EssilorLuxottica SA | $128.90 B |
Becton, Dickinson and Company | $50.81 B |
Alcon Inc. | $44.33 B |
HOYA Corp | $40.30 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. It develops FG001, which is in phase I/II for the treatment of high-grade glioma; and FG002 that allows surgeons to differentiate cancer from normal tissue during surgery through a novel urokinase-type plasminogen activator receptor targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was founded in 2018 and is based in Copenhagen, Denmark.
FluoGuide A/S has the following listings and related stock indices.
Stock: OMX: FLUO wb_incandescent
Stock: FSX: 96X wb_incandescent